SMILTYNINIO ŠLAMUČIO vaistinė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 134,832 | 245,819 | 303,892 | 314,816 | 307,944 | 338,536 | 305,936 | 174,619 |
| Profit before tax | 1,575 | 3,047 | 11,233 | 10,024 | 3,891 | 1,343 | 1,815 | -12,083 |
| Net profit | 1,339 | 2,895 | 9,548 | 8,520 | 3,307 | 1,141 | 1,520 | -12,083 |
| Equity | -2,506 | 389 | 9,937 | 18,457 | 21,764 | 22,905 | 24,425 | 12,360 |
| Liabilities | 48,016 | 54,253 | 35,236 | 43,369 | 18,861 | 23,390 | 31,101 | 6,662 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 | 0 | 6,800 | 0 |
| Current assets | 45,510 | 54,642 | 45,173 | 61,826 | 40,625 | 46,295 | 48,726 | 19,022 |
| Total assets | 45,510 | 54,642 | 45,173 | 61,826 | 40,625 | 46,295 | 55,526 | 19,022 |
|
Financial indicators
|
||||||||
| Revenue change y/y | - | +82.3% | +23.6% | +3.6% | -2.2% | +9.9% | -9.6% | -42.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 2.9% | 5.3% | 21.1% | 13.8% | 8.1% | 2.5% | 2.7% | -63.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 744.2% | 96.1% | 46.2% | 15.2% | 5.0% | 6.2% | -97.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.0% | 1.2% | 3.1% | 2.7% | 1.1% | 0.3% | 0.5% | -6.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 1.2% | 1.2% | 3.7% | 3.2% | 1.3% | 0.4% | 0.6% | -6.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 139.5 | 3.5 | 2.3 | 0.9 | 1.0 | 1.3 | 0.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 70,964 | 122,910 | 151,946 | 157,408 | 153,972 | 169,268 | 152,968 | 87,310 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
SMILTYNINIO ŠLAMUČIO vaistinė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-02-17 | 2023-02-21 | 113.62 |
SMILTYNINIO ŠLAMUČIO vaistinė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-12-18 | 2025-12-18 | 160.14 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
SMILTYNINIO ŠLAMUCIO, UAB is a private limited liability company (code 134715966) engaged in the retail sale of pharmaceutical products. In 2025, the latest financial year, revenue declined to EUR 174.6K from EUR 305.9K in 2024 and EUR 338.5K in 2023, indicating a marked downward trend over the last two years. The company reported a net loss of EUR 12.1K in 2025, compared with net profit of EUR 1.5K in 2024 and EUR 1.1K in 2023. The profit margin turned negative at -6.9% in 2025 after modest positive margins in the prior years. Total assets fell to EUR 19.0K from EUR 55.5K in 2024, while equity decreased to EUR 12.4K and liabilities to EUR 6.7K. The equity ratio stood at 65.0%, and debt-to-equity was 0.54. Asset turnover remained high at 9.18x, reflecting the business’s revenue generation relative to its asset base. Revenue per employee was EUR 87.3K, while profit per employee was negative at EUR 6.0K.